{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:25:05Z","timestamp":1770884705130,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s11899-019-00524-w","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T04:37:41Z","timestamp":1560487061000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Is There a Role for Dose Modification of TKI Therapy in CML?"],"prefix":"10.1007","volume":"14","author":[{"given":"M.","family":"Copland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"issue":"11","key":"524_CR1","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2017.253","volume":"31","author":"R Hehlmann","year":"2017","unstructured":"Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398\u2013406. \n                      https:\/\/doi.org\/10.1038\/leu.2017.253\n                      \n                    .","journal-title":"Leukemia"},{"issue":"24","key":"524_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137. \n                      https:\/\/doi.org\/10.1200\/JCO.2015.66.2866\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"4","key":"524_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, Sandin F, Hoglund M, Stenke L, Bjorkholm M, Lambe M, et al. Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol. 2016;97(4):387\u201392. \n                      https:\/\/doi.org\/10.1111\/ejh.12743\n                      \n                    .","journal-title":"Eur J Haematol"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.leukres.2018.04.008","volume":"69","author":"M Delord","year":"2018","unstructured":"Delord M, Foulon S, Cayuela JM, Rousselot P, Bonastre J. The rising prevalence of chronic myeloid leukemia in France. Leuk Res. 2018;69:94\u20139. \n                      https:\/\/doi.org\/10.1016\/j.leukres.2018.04.008\n                      \n                    .","journal-title":"Leuk Res"},{"issue":"1","key":"524_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337. \n                      https:\/\/doi.org\/10.1182\/blood-2006-01-0092\n                      \n                    .","journal-title":"Blood."},{"issue":"9","key":"524_CR6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u2013102. \n                      https:\/\/doi.org\/10.1038\/leu.2012.85\n                      \n                    .","journal-title":"Leukemia"},{"issue":"3","key":"524_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232\u20138. \n                      https:\/\/doi.org\/10.1200\/JCO.2011.38.6565\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"6","key":"524_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384. \n                      https:\/\/doi.org\/10.1182\/blood-2013-05-501569\n                      \n                    .","journal-title":"Blood."},{"issue":"23","key":"524_CR9","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317. \n                      https:\/\/doi.org\/10.1056\/NEJMoa062867\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"1","key":"524_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17\u201323. \n                      https:\/\/doi.org\/10.1182\/blood-2016-01-694265\n                      \n                    .","journal-title":"Blood."},{"issue":"8","key":"524_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8):1638\u201347.","journal-title":"Leukemia"},{"issue":"4","key":"524_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cncr.25648","volume":"117","author":"J Pinilla-Ibarz","year":"2011","unstructured":"Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer. 2011;117(4):688\u201397. \n                      https:\/\/doi.org\/10.1002\/cncr.25648\n                      \n                    .","journal-title":"Cancer."},{"key":"524_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/cpr.13.43","volume":"10","author":"VE Campbell","year":"2013","unstructured":"Campbell VE, Copland M. Dasatinib for the treatment of chronic phase chronic myeloid leukemia. Clin Pract. 2013;10:415\u201325.","journal-title":"Clin Pract"},{"key":"524_CR14","doi-asserted-by":"crossref","first-page":"Abstract 257","DOI":"10.1182\/blood.V122.21.257.257","volume":"122","author":"H Emir","year":"2013","unstructured":"Emir H, Albrecht-Schgoer K, Grebien F, Eisenwort G, Schgoer W, Kaun C, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood. 2013;122:Abstract 257.","journal-title":"Blood."},{"key":"524_CR15","doi-asserted-by":"crossref","first-page":"Abstract 1503","DOI":"10.1182\/blood.V122.21.1503.1503","volume":"122","author":"DK Hiwase","year":"2013","unstructured":"Hiwase DK, Carne L, Ross D, Grigg A, Hughes TP. Hypercholesterolaemia in imatinib intolerant\/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood. 2013;122:Abstract 1503.","journal-title":"Blood."},{"issue":"28","key":"524_CR16","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486\u201392. \n                      https:\/\/doi.org\/10.1200\/JCO.2011.38.7522\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"4","key":"524_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"\u2022 Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393\u2013404. \n                      https:\/\/doi.org\/10.1182\/blood-2016-09-739086\n                      \n                    \n                              Clinical trial reporting the long term efficacy and safety of ponatinib in the PACE trial\n                              .","journal-title":"Blood."},{"issue":"2","key":"524_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"FX Mahon","year":"2014","unstructured":"Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310\u201322. \n                      https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1988.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"524_CR19","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511\u201321. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1004095\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"8","key":"524_CR20","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"\u2022 Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371. \n                      https:\/\/doi.org\/10.1038\/leu.2016.104\n                      \n                    \n                              Recommendations for the management of side effects of TKIs in CML.","journal-title":"Leukemia"},{"key":"524_CR21","doi-asserted-by":"crossref","unstructured":"Rousselot P, Johnson-Ansah H, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al. Personalized daily doses of Imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results of the randomized OPTIM imatinib study. Blood 2015;126(23):133.","DOI":"10.1182\/blood.V126.23.133.133"},{"issue":"10","key":"524_CR22","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy. Blood. 2008;112(10):3965\u201373. \n                      https:\/\/doi.org\/10.1182\/blood-2008-06-161737\n                      \n                    .","journal-title":"Blood."},{"issue":"6","key":"524_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015;125(6):915\u201323. \n                      https:\/\/doi.org\/10.1182\/blood-2014-07-590315\n                      \n                    .","journal-title":"Blood."},{"issue":"9","key":"524_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"\u2022 Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869\u201374. \n                      https:\/\/doi.org\/10.1002\/ajh.24423\n                      \n                    \n                              Long-term follow-up of CA180-034 study demonstrating that dasatinib 100mg once daily is as efficacious as higher doses with a favourable toxicity profile\n                              .","journal-title":"Am J Hematol"},{"issue":"20","key":"524_CR25","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340. \n                      https:\/\/doi.org\/10.1200\/JCO.2015.64.8899\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"5","key":"524_CR26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354. \n                      https:\/\/doi.org\/10.1038\/leu.2016.5\n                      \n                    .","journal-title":"Leukemia"},{"issue":"1","key":"524_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","volume":"168","author":"TH Brummendorf","year":"2015","unstructured":"Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168(1):69\u201381. \n                      https:\/\/doi.org\/10.1111\/bjh.13108\n                      \n                    .","journal-title":"Br J Haematol"},{"issue":"3","key":"524_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"\u2022 Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231\u20137. \n                      https:\/\/doi.org\/10.1200\/JCO.2017.74.7162\n                      \n                    \n                              Results of the BFORE study highlighting the improved efficacy of bosutinib 400mg daily compared to imatinib, with a better tolerability profile than the 500mg daily dose.","journal-title":"J Clin Oncol"},{"issue":"15","key":"524_CR29","doi-asserted-by":"publisher","first-page":"7002","DOI":"10.1200\/JCO.2018.36.15_suppl.7002","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Mauro MJ, Deininger MWN, Chuah C, Kim DW, Kota V. Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. J Clin Oncol. 2018;36(15):7002. \n                      https:\/\/doi.org\/10.1200\/Jco.2018.36.15_Suppl.7002\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"6","key":"524_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200\u20136. \n                      https:\/\/doi.org\/10.1038\/leu.2008.84\n                      \n                    .","journal-title":"Leukemia"},{"issue":"10","key":"524_CR31","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540\u20136. \n                      https:\/\/doi.org\/10.1182\/blood-2007-03-080689\n                      \n                    .","journal-title":"Blood."},{"key":"524_CR32","first-page":"230","volume":"100","author":"P Rousselot","year":"2015","unstructured":"Rousselot P, Johnson-Ansah H, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al. Individualized imatinib therapy based on [C]min levels monitoring in newly diagnosed cml patients resulted in higher major molecular response rates at 12 months. Results of the Optim-Imatinib Study. Haematologica. 2015;100:230.","journal-title":"Haematologica."},{"key":"524_CR33","first-page":"237","volume":"99","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Mollica L, Guerci-Bresler A, Nicolini FE, Etienne G, Legros L, et al. Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized Optim Dasatinib Trial. Haematologica. 2014;99:237\u20138.","journal-title":"Haematologica."},{"issue":"13","key":"524_CR34","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.31357","volume":"124","author":"K Naqvi","year":"2018","unstructured":"\u2022\u2022 Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018;124(13):2740\u20137. \n                      https:\/\/doi.org\/10.1002\/cncr.31357\n                      \n                    \n                              Early results of clinical trial demonstrating that dasatinib 50mg daily is highly effective with a reduced side effect profile in newly diagnosed CP-CML.","journal-title":"Cancer."},{"issue":"5","key":"524_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139. \n                      https:\/\/doi.org\/10.1182\/blood-2011-08-376087\n                      \n                    .","journal-title":"Blood."},{"issue":"10","key":"524_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00277-007-0326-2","volume":"86","author":"AM Carella","year":"2007","unstructured":"Carella AM, Lerma E. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol. 2007;86(10):749\u201352. \n                      https:\/\/doi.org\/10.1007\/s00277-007-0326-2\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"26","key":"524_CR37","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","volume":"121","author":"D Russo","year":"2013","unstructured":"Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138\u201344. \n                      https:\/\/doi.org\/10.1182\/blood-2013-01-480194\n                      \n                    .","journal-title":"Blood."},{"key":"524_CR38","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1200\/JCO.2017.35.15_suppl.7051","volume":"35","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Hochhaus A, Kantarjian HM, Guilhot F, Kota VK, Hughes TP, et al. Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION. J Clin Oncol. 2017;35:7051. \n                      https:\/\/doi.org\/10.1200\/Jco.2017.35.15_Suppl.7051\n                      \n                    .","journal-title":"J Clin Oncol"},{"issue":"3","key":"524_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ejh.12423","volume":"94","author":"H Hjorth-Hansen","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015;94(3):243\u201350. \n                      https:\/\/doi.org\/10.1111\/ejh.12423\n                      \n                    .","journal-title":"Eur J Haematol"},{"issue":"1","key":"524_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.9035-17","volume":"57","author":"N Iriyama","year":"2018","unstructured":"Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, et al. The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the Kanto CML Study Group. Intern Med. 2018;57(1):17\u201323. \n                      https:\/\/doi.org\/10.2169\/internalmedicine.9035-17\n                      \n                    .","journal-title":"Intern Med"},{"issue":"5","key":"524_CR41","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s10147-018-1300-9","volume":"23","author":"S Mizuta","year":"2018","unstructured":"Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, et al. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018;23(5):980\u20138. \n                      https:\/\/doi.org\/10.1007\/s10147-018-1300-9\n                      \n                    .","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"524_CR42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00277-013-1769-2","volume":"92","author":"P La Rosee","year":"2013","unstructured":"La Rosee P, Martiat P, Leitner A, Klag T, Muller MC, Erben P, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013;92(10):1345\u201350. \n                      https:\/\/doi.org\/10.1007\/s00277-013-1769-2\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"3","key":"524_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.2010.08245.x","volume":"150","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Fava C, O\u2019Brien S, Garcia-Manero G, Ravandi F, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010;150(3):303\u201312. \n                      https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08245.x\n                      \n                    .","journal-title":"Br J Haematol"},{"key":"524_CR44","unstructured":"\u2022 Rea D, Cayuela JM, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood 2017;130(23):318 Demonstration of the efficacy of a once daily dosing strategy for Nilotinib."},{"issue":"9","key":"524_CR45","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2013-07-513937","volume":"123","author":"HM Kantarjian","year":"2014","unstructured":"Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309\u201318. \n                      https:\/\/doi.org\/10.1182\/blood-2013-07-513937\n                      \n                    .","journal-title":"Blood."},{"key":"524_CR46","doi-asserted-by":"publisher","unstructured":"Brummendorf TH, Gambacorti-Passerini C, Hochhaus A, Lipton JH, Kota V, Deininger MW, et al. Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial. Blood. 2018;132. \n                      https:\/\/doi.org\/10.1182\/blood-2018-99-110543\n                      \n                    .","DOI":"10.1182\/blood-2018-99-110543"},{"issue":"19","key":"524_CR47","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1306494\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"5","key":"524_CR48","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612\u201321. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(16)00080-2\n                      \n                    .","journal-title":"Lancet Oncol"},{"key":"524_CR49","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3324\/haematol.2018.206797","volume":"104","author":"C Michel","year":"2018","unstructured":"Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, et al. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018;104:955\u201362. \n                      https:\/\/doi.org\/10.3324\/haematol.2018.206797\n                      \n                    .","journal-title":"Haematologica."},{"issue":"1","key":"524_CR50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00277-016-2839-z","volume":"96","author":"F Cervantes","year":"2017","unstructured":"Cervantes F, Correa JG, Perez I, Garcia-Gutierrez V, Redondo S, Colomer D, et al. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol. 2017;96(1):81\u20135. \n                      https:\/\/doi.org\/10.1007\/s00277-016-2839-z\n                      \n                    .","journal-title":"Ann Hematol"},{"issue":"7","key":"524_CR51","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"RE Clark","year":"2017","unstructured":"\u2022\u2022 Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310\u2013e6. \n                      https:\/\/doi.org\/10.1016\/S2352-3026(17)30066-2\n                      \n                    \n                              Interim results of the DESTINY clinical trial demonstrating that dose reduction is safe and molecular responses are maintained in the vast majority of patients in MMR and DMR, with a marked improvement in side effects\n                              .","journal-title":"Lancet Haematol"},{"key":"524_CR52","unstructured":"\u2022 Clark R, Polydoros F, Apperley J, Milojkovic D, Rothwell K, Pocock C, et al. Final results of the DESTINY study of de-escalation and stopping treatment in chronic myeloid leukaemia. EHA 2018; EHA Learning Center: Abstract S809 Final results of the DESTINY clinical showing high rates of successful TFR in patients entering trial in DMR with a further reduction in TKI-related side effects."},{"issue":"25","key":"524_CR53","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(25):2821\u20133. \n                      https:\/\/doi.org\/10.1200\/JCO.2014.55.6910\n                      \n                    .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"524_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"\u2022 Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357. \n                      https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X\n                      \n                    \n                              Interim analysis of the EUROSKI clinical trial.","journal-title":"Lancet Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00524-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00524-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T23:13:09Z","timestamp":1592003589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00524-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00524-w","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"14 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"M. Copland reports personal fees and other from Ariad\/Incyte, personal fees and non-financial support from Novartis Pharma, personal fees and non-financial support from Bristol-Myers Squibb, and personal fees from Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}